Cofactor Genomics to Provide Solid Tumor Immune Profiling for Genocea Biosciences

Dec. 4, 2018 14:00 UTC

-- Pilot study to evaluate use of Cofactor assay in Genocea’s neoantigen vaccine clinical trial --

SAN FRANCISCO--(BUSINESS WIRE)-- Cofactor Genomics, a clinical RNA sequencing and translational assay developer, today announced a pilot study to evaluate use of Cofactor’s ImmunoPrismTM assay in Genocea Biosciences Phase 1/2a clinical trial testing the safety and efficacy of its lead personalized cancer vaccine candidate, GEN-009, in adult cancer patients with a variety of solid tumors.

The pilot study is designed to enable Genocea to comprehensively characterize the immune responses that patients enrolled in the clinical trial generate in response to vaccination. The RNA-based assay developed by Cofactor should enable Genocea to compare the immune cell composition for 8 major immune types within and between patients, including expression reporting for key immune escape genes.

“We are working to develop truly effective personalized neoantigen vaccines with which to treat cancer patients. Through exploration of advanced technologies like Cofactor’s ImmunoPrism assay, we aim to better understand the intratumoral immune responses we are eliciting in response to our vaccine,” said Jessica Baker Flechtner, Ph.D., Chief Scientific Officer at Genocea.

“Pilot studies such as this one, where our technology is implemented in the field to empower drug developers to find the most robust markers of therapeutic success, are extremely important in validating our cutting-edge technology,” noted David Messina, Chief Operating Officer at Cofactor Genomics. “Demonstrating the utility of a new approach to immune profiling is best accomplished with partners like Genocea, who are eager to gain access to the most innovative and advanced assays.”

Cofactor Genomics recently announced the release of their ImmunoPrism Immune Profiling Kit, which enables access to their proprietary molecular and machine-learning informatics for RNA analysis of the tumor microenvironment. The ImmunoPrism kit offers laboratories the ability to validate the assay, as Cofactor has done through their CAP-accredited laboratory.

Cofactor will present the results of this clinical validation work during an upcoming webinar titled, “Clinical Validation of a Multidimensional Pan-Cancer Immune Assay” on Thursday, December 13 at 11 AM EST: http://www.clinicalinformaticsnews.com/cofactor-genomics/clinical-validation/

About Cofactor Genomics, Inc.

Cofactor Genomics uses RNA to help researchers and clinicians understand, diagnose, and predict drug response for the 95% of disease that can’t be assessed by DNA alone. Founded by three former Human Genome Project scientists, Cofactor has built a database of multidimensional gene expression models, and a proprietary platform capable of overcoming the chemical and computational challenges of performing complex characterization of clinical-grade human samples. Cofactor has contracts to provide RNA sequencing and analysis services to the research arms of eight of the world’s largest pharma and biotech companies and is in the process of commercializing a suite of clinical diagnostic assays. Find out more about Cofactor Genomics at cofactorgenomics.com.

About Genocea Biosciences, Inc.

Genocea's mission is to help conquer cancer by designing and delivering targeted cancer vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is currently studying the safety, immunogenicity, and efficacy of its lead neoantigen cancer vaccine, GEN-009, in a Phase 1/2a clinical trial. For more information, please visit www.genocea.com.

 

Contacts

Terri Clevenger
Continuum Health Communications/ICR
tclevenger@continuumhealthcom.com
(203) 856-4326

 
 

Source: Cofactor Genomics, Inc.

Back to news